{
  "docId": "019de514-6ff5-7310-813b-bef8d5f9ec91",
  "docSlug": "dbbeae38634aeeee4a36f290777f18f9",
  "documentTitle": "Vivani Medical | Mergers and Acquisitions Presentation Deck | 27 slides",
  "authorId": "vivani-medical",
  "authorName": "Vivani Medical",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 27,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de514-6ff5-7310-813b-bef8d5f9ec91/11",
  "deckHref": "/decks/019de514-6ff5-7310-813b-bef8d5f9ec91",
  "deckJsonHref": "/decks/019de514-6ff5-7310-813b-bef8d5f9ec91.json",
  "deckAnchorHref": "/decks/019de514-6ff5-7310-813b-bef8d5f9ec91#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.5,
        "y": 0.25
      },
      "kind": "list",
      "text": "Non-adherence is the primary reason for low, real-world effectiveness. Guaranteed adherence will produce significant healthcare cost savings. FDA indicated 505(b)(2) streamlined approval pathway may be available. ~$54M raised pre-merger from investors including AstraZeneca",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "669d0e55-2899-48a8-8fea-4b01134d0982",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.02,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "1 Guo 2016; 2 Carls et al., 2017; 3 IMS 2013 Report",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d7d6dea2-c996-4930-8cd1-a4a095988040",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.05,
        "y": 0.38
      },
      "kind": "title",
      "text": "Lead Product (NPM-119): 6-Month Exenatide (Glucagon-like Peptide 1 Receptor Agonist) Implant for Type 2 Diabetes",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "764b077c-3cb6-409f-b64d-a301fb4b9def",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}